Dr. Laurie Glimcher, President and CEO of the Dana-Faber Cancer Institute (DFCI), is justifiably concerned that Congress is not providing sufficient funding for the NIH. She expressed her worries last week at the Forbes Healthcare Summit in NYC saying that “places like the DFCI are where new drugs are born” and that “decreased funding to the NIH is killing early research.” She went on to point out that “many medicines would not exist without NIH support.”


More at: https://www.forbes.com/sites/johnlamattina/2017/12/04/dana-farber-cancer-institute-ceo-wants-to-tax-biopharma-to-pay-for-the-nih/#b0665c95ff20

Editorial Team
Author: Editorial Team